Study Evaluating EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy
Status:
Terminated
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
EAA-090 is being developed for the treatment of neuropathic pain associated with diabetic
neuropathy. It is a selective antagonist that binds competitively to the glutamate site of
the N-methyl-D-aspartate (NMDA) receptor.
This study will assess the safety and efficacy of 3 fixed oral doses of EAA-090 compared with
placebo in subjects with neuropathic pain associated with diabetic neuropathy.